Interleukin 17 deficiency and implications in cutaneous and systemic diseases  by Welch, Elizabeth Z. et al.
Available online at www.sciencedirect.com
www.jdds.orgScienceDirect
Journal of Dermatology & Dermatologic Surgery 19 (2015) 73–79Review
Interleukin 17 deﬁciency and implications in cutaneous and
systemic diseases
Elizabeth Z. Welch a, Kathryn L. Anderson a, Steven R. Feldman a,b,c,⇑
aCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, United States
bDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, United States
cDepartment of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, United States
Received 18 February 2015; accepted 2 March 2015
Available online 3 April 2015Abstract
Background: IL17-targeted therapeutics are being developed to treat psoriasis. IL17 is involved in the pathogenesis of many diseases,
and the implications of IL17 blockade are not yet well characterized.
Objective: To review the implications of IL17 deﬁciency to determine potential implications of IL17 blockade.
Methods: PubMed was searched for articles related to; basic biology of IL17, in vitro and in vivo studies of IL17 deﬁciency, animal or
human models of IL17 deﬁciency, and induced deﬁciency with anti-IL17 deﬁciency. Of 104 articles, 46 were included in this review.
Results: Deﬁciencies in the IL17 pathway can result in both bacterial and fungal infections and increased tumor growth. IL17
deﬁciency states are associated with susceptibility to infections from Staphylococcus aureus, Mycobacterium tuberculosis and Candida
albicans. IL17 deﬁciency attenuates rheumatoid arthritis, atopic dermatitis, hapten-induced contact hypersensitivity and irritable bowel
disease and is protective in lung cancer.
Limitations: Ultimately, clinical trials will determine the side eﬀects of IL17 targeted therapeutics.
Conclusion: The implications of the information found in this review demonstrate potential eﬀects to consider when using IL17 tar-
geted therapeutics in the treatment of psoriasis.
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Until recently, many autoimmune diseases were cat-
egorized by being either Th1 or Th2 mediated. Th17 cells
have since been implicated in many autoimmune diseases
and are of particular interest in psoriasis and potential
therapeutics. Th17 cells produce cytokines including
IL17A, IL17F, IL17AF, IL21, IL22, and IL26 (Chiricozzi
and Krueger, 2013). The Th17 system is implicated in the
pathogenesis of diseases including systemic erythematous
lupus (SLE), multiple sclerosis (MS), rheumatoid arthritis
(RA), atopic dermatitis (AD), and contact hypersensitivity
(CHS) (Raychaudhuri, 2013). Therapeutics for psoriasis
are currently being developed which target IL17 including,
secukinumab, ixekizumab, and brodalumab. Clinical trials
will likely elicit common events associated with the drug
and have a placebo group to which adverse event rates
can be compared. Once the drugs are used without a pla-
cebo group, less common side eﬀects may arise, and it
may be diﬃcult to know which of those events are truly
related to the drug. Understanding the implications of
IL17 deﬁciency may help determine which side eﬀects are
likely related to the drug.2. Methods
Candidate articles were identiﬁed via PubMed search of
the keywords “IL17 AND Deﬁciency”, “IL17 AND side
eﬀects”, “IL17 AND inﬂammation AND action”, “IL17
AND psoriasis”, “IL17 AND immunity” AND “IL17
AND immune diseases”, “IL17 AND infections”, and
“IL17 AND comorbidities.” Search criteria included
articles written in English and published from January
1999 to January 2015. From these search terms, 455 papers
were identiﬁed. Initial screening looked at article title.Information was organized into the following categories;
basic biology of IL17, in vitro and in vivo studies of
IL17 deﬁciency, animal and human models of IL17 deﬁ-
ciency, and induced deﬁciency with anti-IL17 drugs. Of
the 455 papers identiﬁed upon initial search, 104 articles
ﬁt into the categories described, and further analysis was
done by reading the article abstracts. For inclusion,
abstracts of the selected papers must have included infor-
mation pertaining to IL17 function in disease states and/
or IL17 deﬁciency states leading to disease. Of the 104
papers, 46 articles were identiﬁed for inclusion in this
review.3. Results/discussion
3.1. Biology of IL17 and implication in psoriasis
While IL17 has been implicated in many autoimmune
diseases, it has been strongly associated with psoriasis
and ankylosing spondylitis. New therapeutics have
emerged that target the IL17 pathway leading to its down
regulation. Before looking at IL17 deﬁciency states it is
important to understand the biology of IL17. The IL17
family consists of 6 cytokines. Of particular interest are
pro-inﬂammatory cytokines, IL17A and IL17F. These
two cytokines have the strongest sequence homology
among members of the IL17 cytokine family. Due to its
greater aﬃnity for the IL17 receptor (IL17R), IL17A has
been the target of emerging therapeutics such as ixekizu-
mab and secukinumab (Chiricozzi and Krueger, 2013).
Both Th17 and Tc17 cells, the major IL17 producing cells,
inﬁltrate psoriatic skin to a greater extent than those
without disease (Jin and Dong, 2013; Chiricozzi and
Krueger, 2013). Psoriatic lesions also have high expression
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these lesions (Chiricozzi and Krueger, 2013).
3.2. Adverse eﬀects of IL17 deﬁciency
While IL17 targeted therapeutics show promise for dis-
eases like psoriasis, the mechanism of action in other dis-
ease systems can elucidate potential adverse eﬀects of
IL17 targeted therapeutics. Some of these potential adverse
eﬀects include atherosclerotic plaque formation and
increased risk of infections.
3.2.1. Atherosclerosis
The role of IL17 in atherosclerosis is controversial (Gao
et al., 2010; Danzaki et al., 2012). Most recently, a mouse
model showed IL17 deﬁciency was pro-atherosclerotic.
Apolipoprotein e/IL17 double deﬁcient mice (IL17A/
ApoE/) showed IL17A plays a protective role in athero-
sclerosis. IL17A/ApoE/ mice have inducible athero-
sclerosis with overfeeding. IL17A is up-regulated in diet
induced atherosclerosis, and IL17 deﬁciency stabilizes
formed plaques through reduced leukocyte inﬁltration
(Madhur et al., 2011).
3.2.2. IL17 and immunity
An important implication in IL17 deﬁciency is the
possibility of reducing innate and T cell immunity which
could ultimately lead to an increased risk of infections
(Nakae et al., 2002). IL17-neutralized mice exhibit
delayed clearance of chlamydial bacteria, obligate intra-
cellular bacteria, and have more severe lung infections
than wild type mice (Bai et al., 2009). The proposed
mechanism by which IL17 deﬁciency leads to increased
infection is an alteration in phenotype and function of
dendritic cells leading to failure in the development of
protective type 1 immunity. The IL17/Th17 pathway is
involved in protective eﬀects against extracellular patho-
gens like Klebsiella pneumonia, Citrobacter rodentium,
Escherichia coli and Staphylococcus aureus. IL17R-deﬁ-
cient mice have increased bacterial dissemination into
spleen, greater bacterial recovery of K. pneumonia from
the lung, and increased periodontal disease induced by
Porphyromonas gingivalis (Curtis and Way, 2009).
IL17R-deﬁcienct mice have a delay in neutrophil recruit-
ment into the alveolar space, higher dissemination of K.
pneumonia, and over twice the mortality rates compared
to wild type controls (Ye et al., 2001). IL17R-deﬁcient
mice have larger skin lesions and a higher bacterial
count of S. aureus, the most common cause of skin
and soft tissue infections, than wild type control mice
(Cho et al., 2010). While IL17R-deﬁciency is associated
with a higher bacterial load, IL17A and IL17F are lar-
gely redundant in function in the defense of S. aureus;
IL17A or IL17F is suﬃcient for protection against S.
aureus (Ishigame et al., 2009; Jin and Dong, 2013).Microarray analysis in cynomolgus macaques following
BCG-vaccination and tuberculosis (TB) challenge identi-
ﬁed IL17 as important in immunity against TB. IL17 is
upregulated at 6 weeks post TB challenge in both vacci-
nated and unvaccinated animals, suggesting that BCG
vaccination induces IL17 and protective immune responses
and that unvaccinated animals produce IL17 through
innate, adaptive immunity (Wareham et al., 2014). In a
mouse model, IL17 plays a role in early protective immu-
nity against Mycobacterium tuberculosis. Overexpression
of IL17 restores protective immunity in IL17A deﬁcient
mice that were challenged with a hypervirulent strain
(Mtb HN878) of M. tuberculosis. IL17 deﬁcient mice were
more susceptible to infection with Mtb HN878 but not to
infection with all clinical isolates of M. tuberculosis such
as Mtb H37RV or Mtb CDC1551 suggesting that IL17
involvement following M. tuberculosis infection could be
strain speciﬁc (Gopal et al., 2014).
IL17 plays an important role in fungal infections, particu-
larly in Candida infections which can cause superﬁcial infec-
tions of the skin, oral, and vaginal mucosa, or it can
disseminate systemically (Gladiator et al., 2013). Both
IL17A and IL23 deﬁcient mice developed Candida albicans
skin lesions that took longer to heal thanwild typemice while
exogenous IL17A promoted healing in mice deﬁcient in IL23
(Kagami et al., 2010). Defects in IL17 production or function
yieldmiceunable to controlmucosal and cutaneous infections
or systemic dissemination of C. albicans in mice (Gladiator
et al., 2013). Innate lymphoid cells producing IL17 are essen-
tial and suﬃcient for IL17-mediated protective immunity
against fungal infections in the oral mucosa.
While IL17 has been linked to innate lymphoid cells, it is
also necessary for the competence of natural killer (NK)
cells and the proper functioning of NK cell mediated
immunity against diﬀerent types of infectious agents.
Mice deﬁcient in IL17R or unable to secrete IL17 are
highly susceptible to systemic candidiasis; impaired
development of functional NK cells leads to susceptibility
to systemic fungal infections (Bar et al., 2014). Both
IL17RA deﬁcient and NK cell depleted mice died rapidly
in response to systemic infection with C. albicans. This
infection was associated with massive fungal burden in
the kidneys at 3 days post-infection when compared to wild
type controls (Bar et al., 2014). Not only is IL17 necessary
for NK cell mediated immunity, but it may be necessary for
NK cell mediated protection against tumors (discussed
below) (Kryczek et al., 2009).
In humans, mutations in IL17R and IL17F along with
mutations in STAT3, which is critical to induction of
Th17 responses, occur in patients with chronic mucocuta-
neous candidiasis (CMC) (Sillevis Smitt and Kuijpers,
2013). Patients with CMC have decreased production of
IL17A and IL22 (Huppler et al., 2012). They may have
an autosomal recessive IL17RA (a subunit of the hetero-
meric IL17R complex) deﬁciency or autosomal dominant
IL17F deﬁciency (Cypowyj et al., 2012;Liu et al., 2011).
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immunodeﬁciency disease characterized by recurrent
staphylococcal skin infections, lung infections, eczema,
and eosinophilia (Ma et al., 2008). STAT3 is necessary
for the development of Th17 cells, which subsequently
induce IL17. Mutations in STAT3 cause failure of genera-
tion of IL17 producing CD4+ Th17 cells. Five unrelated
patients with HIES and history of invasive S. aureus infec-
tions were identiﬁed and all had mutations in STAT3, con-
ferring Th17 deﬁciency and ultimately IL17 deﬁciency (Ma
et al., 2008). Patients with HIES with IL17 deﬁciency are
susceptible to bacterial and fungal infections (Paulson
et al., 2008). The possibility of increased susceptibility to
infection from a multitude of infectious agents can be con-
sidered with anti-IL17 therapies.
3.2.3. Tumor growth and proliferation
An IL-17 deﬁciency state may have a protective role or a
harmful role in tumorigenesis. Interferon-c (IFN-c) inhi-
bits tumor proliferation and angiogenesis. In IL17 deﬁcient
mice, enhanced lung and subcutaneous tumor growth and
metastasis is correlated to a decrease in the number of IFN-
c producing natural killer (NK) cells (Kryczek et al., 2009).
Following colon cancer induction, there was an increase in
colonic tumor numbers and tumor areas in mice with deﬁ-
cient IL17F, compared to wild type (Tong et al., 2012). In
patients with colon cancer there are lower mRNA levels of
IL17F in the cancerous tissue compared to the normal tis-
sue in surgically resected bowels. Transfection of IL17F
cDNA into a colon cancer cell line leads to inhibition of
colon tumorigenesis in vivo (Tong et al., 2012).
3.3. Beneﬁcial eﬀects of IL17 deﬁciency
While there are potential negative implications of IL17
deﬁciency, there may be beneﬁts of blocking IL17. IL17-
deﬁcient animals have lower tumor growth in lung cancer
and lymphoma in animal models, and decreased incidence
of rheumatoid arthritis, atopic dermatitis, systemic ery-
thematous lupus, atopic dermatitis, contact hypersensitiv-
ity, and inﬂammatory bowel diseases.
3.3.1. Tumor growth and proliferation
The role of IL17 and Th7 in tumor pathogenesis is
controversial. Reppert et al. investigated the role of IL17
in lung cancer. Mice treated with anti-IL17A have reduced
tumor growth in the lung and increased survival.
Treatment with anti-IL17 also increases production of
IFN-c which inhibits tumor proliferation and angiogenesis.
Anti-IL17A antibody inhibits enterotoxigenic Bacteroides
fragilis induced colitis, colonic hyperplasia, and tumor for-
mation in mice (Wu et al., 2009). Mice deﬁcient in IL17R
have increased CD8 T cell inﬁltration and reduced inﬁltra-
tion of myeloid derived suppressor cells (MDSC), which
promote proliferation at tumor sites after inoculation with
a high-immunogenic lymphoma cell line. This suggests that
IL17 is required for MDSC-mediated tumor promotingactivity. Administration of exogenous IL17 promotes
tumor growth via regulation of myeloid derived suppressor
cells (He et al., 2010). These studies along with the studies
outlined previously, suggest that the role of IL17 in
tumorigenesis may be either tumor promoting or necessary
for tumor immunity and may depend on the tumor type
and host.
3.3.2. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inﬂammatory
autoimmune disorder that aﬀects small joints in hands
and feet resulting in thickened synovium in joints ulti-
mately destroying cartilage and bone. IL17 is expressed
to a higher level in the synovium of patients with RA
compared to those without disease (Kotake et al., 1999).
IL17-targeted therapies may be beneﬁcial in RA (Kellner,
2013). Mouse models with collagen induced arthritis were
treated with anti-IL17 antibody positive serum or IL17R
ImmunoglobulinG1 Fc fusion protein both leading to sig-
niﬁcantly reduced severity of collagen induced arthritis
(Bush et al., 2002;Kellner, 2013). Anti-IL17 therapy sup-
presses joint inﬂammation and prevents cartilage and bone
destruction (Lubberts et al., 2004). IL17 is also important
for the activation of autoantigen-speciﬁc T and B cells in
the sensitization phase of collagen induced arthritis
(Nakae et al., 2002). Joint swelling and cartilage damage
are reduced in IL17R deﬁcient mice (Plater-Zyberk et al.,
2009). IL17 promotes bone resorption by acting on
osteoblasts to stimulate cyclooxygenase-2 dependent pros-
taglandin E 2 synthesis of osteoblast diﬀerentiation factor
gene expression (Kotake et al., 1999).
An association between RA and systemic lupus erythe-
matosus (SLE) has been suggested. Similar to RA, IL17
is elevated in the serum of patients with SLE compared
to patients without SLE (Doreau et al., 2009). In IL17 suf-
ﬁcient wild-type mice, induction of SLE was possible, but
not in IL17 deﬁcient mice, suggesting IL17 deﬁciency is
protective from SLE (Amarilyo et al., 2014). Forced
expression of IL17 enhanced the severity of lupus nephritis
while blockage of IL17 decreased the severity of lupus
nephritis in mice (Wen et al., 2013).
3.3.3. Atopic dermatitis and hapten induced contact
hypersensitivity
Atopic dermatitis (AD) is a common skin disease
characterized by scaly patches on the skin of the scalp,
forehead and face that typically manifests in the ﬁrst year
of life. Th2 mediated immune responses have been linked
to AD and other skin diseases such as hapten-induced con-
tact hypersensitivity (CHS). CHS represents a delayed type
hypersensitivity of cellular immune responses mediated by
CD8+ T cells that produce IL17 or IFN-c which is elicited
upon exposure to haptens, small molecules that promote
an immune response in the body. IL17 may be a key com-
ponent of the inﬂammatory pathway that leads to AD and
CHS (Nakajima et al., 2014;He et al., 2009;Peiser, 2013).
Murine AD models deﬁcient in IL17 have decreased
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induction (Nakajima et al., 2014). Similarly, inﬁltration
of granulocytes and macrophages in hapten challenged
skin of IL17R deﬁcient mice is reduced leading to overall
decrease in CHS responses in these mice. Upon injection
of IL17 into the skin, high levels of leukocyte inﬁltration
and inﬂammation are induced (He et al., 2009). IL17
deﬁcient mice have suppressed CHS responses compared
to IL17 suﬃcient mice (Nakae et al., 2002;Peiser, 2013).
These studies suggest IL17A mediates Th2 type immune
responses in the pathogenesis of AD and CHS leading to
the possibility of targeting IL17 through therapeutics in
the treatment of these dermatologic diseases.
3.3.4. Inﬂammatory bowel diseases
Ulcerative colitis (UC) and Crohn’s disease (CD) classi-
cally are thought to rely on Th2 and Th1 responses respec-
tively (Yamada, 2010). However, mice deﬁcient in both
IL17 and IL6 have a decrease in severity of IBD (Yen
et al., 2006). In human inﬂammatory bowel disease (IBD)
lesions, there is overexpression of Th17 related molecules,
and IL17 mRNA is expressed in the inﬂamed colonic tissue
from both CD and UC, suggesting that Th17 cells may
play a role in the development of IBD (Yamada,
2010;Nielsen et al., 2003).
While IL17 has been implicated in IBD lesions, the
IL12/IL23 axis of the Th17 response has been successfully
targeted for therapeutics in CD (Burakoﬀ et al., 2006;Elson
et al., 2007). IL23 is involved in the pathogenesis of IBD by
inducing inﬂammation through IL17 and IL6 (Yen et al.,
2006;Elson et al., 2007).
3.3.5. Other disease implications
Leukocyte adhesion deﬁciency (LAD) is a rare disease
of immunodeﬁciency resulting in impaired neutrophil
adhesion leading to recurrent infections. Mouse models
suggest that the IL23/IL17 axis is dysregulated in LAD
type 1 (LAD-1) (Stark et al., 2005). In patients with
LAD-1, high levels of IL17A mRNA are expressed. Mice
treated with anti-IL17A or anti-IL23 were protected from
bone loss and resembled a phenotype similar to wild-type
mice (Moutsopoulos et al., 2014).
Pravastatin, a widely used drug to treat hyperlipidemia,
suppresses systemic sensitization to allergens in allergic air-
way inﬂammation through the down regulation of IL17
production. This ﬁnding may indicate the possibility of
targeting IL17 in allergic airway inﬂammation (Imamura
et al., 2009).
4. Conclusion
IL17 is implicated in many disease models and in the
immune reaction to many infectious agents. IL17-targeted
drugs are being developed to treat psoriasis and are cur-
rently being tested for diseases like rheumatoid arthritis
as well. These drugs, which may confer a relative IL17 deﬁ-
ciency-like state, may have both adverse and beneﬁcialeﬀects. Before side eﬀects become more evident, we can
attempt to predict from IL17 deﬁciency states and mecha-
nism of actions what may happen when IL17 is targeted
with inhibitors.
The role of IL17 in atherosclerosis is controversial. Since
it may promote atherosclerosis, it is another reason as to
why attention to diet and weight gain may be of impor-
tance in the treatment of psoriasis, particularly with anti-
IL17 therapies. IL17 deﬁciency models have increased risk
of bacterial infection with increased bacterial load and dis-
semination, delayed neutrophil recruitment and clearance
of bacteria, and more severe infections. Risk of fungal
and viral infections is also increased in IL17 deﬁciency
states. Patients with HIES and IL17 deﬁciency are
susceptible to increased bacterial and fungal infections.
Along with its role in immunity, IL17 deﬁciency states
are involved with tumor growth and proliferation. In colon
cancer models, IL17 deﬁciency leads to an increase in
tumor numbers and enhanced tumor growth.
The IL17 deﬁciency state does not only confer dele-
terious eﬀects in disease models but also shows potentially
beneﬁcial eﬀects. Contrary to some studies, IL17 deﬁciency
state may lead to decreased tumor growth and angiogene-
sis. Anti-IL17 therapy also suppresses joint inﬂammation
and prevents cartilage and bone destruction in RA. IL17
is elevated in both RA and SLE and forced expression of
IL17 enhanced the severity of SLE, suggesting an IL17
deﬁcient state may help these diseases. IL17 has been
linked to AD and CHS and may be a key component in
the Th2 type immune response leading to these dermato-
logic conditions. IL17 may also play a role in the inﬂamma-
tory cascade that leads to UC and CD; deﬁciency in IL17
and IL6 leads to decreased severity of IBD.Conﬂict of interest
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